JP2024515100A5 - - Google Patents
Info
- Publication number
- JP2024515100A5 JP2024515100A5 JP2023564130A JP2023564130A JP2024515100A5 JP 2024515100 A5 JP2024515100 A5 JP 2024515100A5 JP 2023564130 A JP2023564130 A JP 2023564130A JP 2023564130 A JP2023564130 A JP 2023564130A JP 2024515100 A5 JP2024515100 A5 JP 2024515100A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- use according
- treatment
- ctla4
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000009926 | 2021-04-20 | ||
| IT102021000009926A IT202100009926A1 (it) | 2021-04-20 | 2021-04-20 | Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4 |
| PCT/EP2022/060287 WO2022223543A1 (en) | 2021-04-20 | 2022-04-19 | A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515100A JP2024515100A (ja) | 2024-04-04 |
| JP2024515100A5 true JP2024515100A5 (enExample) | 2025-03-14 |
| JP7902198B2 JP7902198B2 (ja) | 2026-08-07 |
Family
ID=76808052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564130A Active JP7902198B2 (ja) | 2021-04-20 | 2022-04-19 | 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240207228A1 (enExample) |
| EP (1) | EP4326259A1 (enExample) |
| JP (1) | JP7902198B2 (enExample) |
| KR (1) | KR20230172001A (enExample) |
| CN (1) | CN117177745A (enExample) |
| AR (1) | AR125356A1 (enExample) |
| AU (1) | AU2022262199A1 (enExample) |
| BR (1) | BR112023021125A2 (enExample) |
| CA (1) | CA3213275A1 (enExample) |
| CL (1) | CL2023002894A1 (enExample) |
| CO (1) | CO2023013780A2 (enExample) |
| IL (1) | IL307649A (enExample) |
| IT (1) | IT202100009926A1 (enExample) |
| MX (1) | MX2023012030A (enExample) |
| PE (1) | PE20242078A1 (enExample) |
| TW (1) | TW202308609A (enExample) |
| WO (1) | WO2022223543A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119424649A (zh) * | 2024-02-29 | 2025-02-14 | 中山大学附属第一医院 | 假体周围感染治疗靶点及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190022203A1 (en) | 2016-01-11 | 2019-01-24 | Turnstone Limited Partnership | Oncolytic virus and checkpoint inhibitor combination therapy |
| IT201700041723A1 (it) * | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
-
2021
- 2021-04-20 IT IT102021000009926A patent/IT202100009926A1/it unknown
-
2022
- 2022-03-25 TW TW111111338A patent/TW202308609A/zh unknown
- 2022-04-18 AR ARP220100959A patent/AR125356A1/es unknown
- 2022-04-19 IL IL307649A patent/IL307649A/en unknown
- 2022-04-19 PE PE2023002749A patent/PE20242078A1/es unknown
- 2022-04-19 EP EP22723425.9A patent/EP4326259A1/en active Pending
- 2022-04-19 MX MX2023012030A patent/MX2023012030A/es unknown
- 2022-04-19 BR BR112023021125A patent/BR112023021125A2/pt unknown
- 2022-04-19 CN CN202280027381.5A patent/CN117177745A/zh active Pending
- 2022-04-19 US US18/555,103 patent/US20240207228A1/en active Pending
- 2022-04-19 WO PCT/EP2022/060287 patent/WO2022223543A1/en not_active Ceased
- 2022-04-19 KR KR1020237039421A patent/KR20230172001A/ko active Pending
- 2022-04-19 JP JP2023564130A patent/JP7902198B2/ja active Active
- 2022-04-19 CA CA3213275A patent/CA3213275A1/en active Pending
- 2022-04-19 AU AU2022262199A patent/AU2022262199A1/en active Pending
-
2023
- 2023-09-28 CL CL2023002894A patent/CL2023002894A1/es unknown
- 2023-10-19 CO CONC2023/0013780A patent/CO2023013780A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230310595A1 (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| US11648223B2 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| JP6757959B2 (ja) | 抗がん剤 | |
| JP2022533578A5 (enExample) | ||
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| CN109985237B (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2015517523A5 (enExample) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| FI114011B (fi) | Suonensisäiseen käyttöön tarkoitetun immunoglobuliinin käyttö farmaseuttisen koostumuksen valmistamiseksi syöpäsairauksien hoitamiseksi | |
| Chen et al. | A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| JP6373252B2 (ja) | オーロラキナーゼ阻害薬を使用する癌の治療方法 | |
| WO2021057764A1 (zh) | Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途 | |
| CN114340672B (zh) | 包含hdac抑制剂和抗pd1抗体或抗pd-l1抗体的药物组合物 | |
| CN110507651B (zh) | 一种具有抗非小细胞肺癌作用的药物及其用途 | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| JPWO2022270523A5 (enExample) | ||
| WO2017177515A1 (zh) | 4-羟基水杨酰苯胺在制备抗骨髓瘤、淋巴瘤药物中的应用 | |
| CN110494137A (zh) | 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途 | |
| AU2015242786A1 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| TWI882612B (zh) | 藥物組合及其應用 | |
| JP6143169B2 (ja) | 膵臓癌治療剤 |